On the preparation of a therapeutic dose of 177Lu-labeled DOTA-TATE using indigenously produced 177Lu in medium flux reactor

Applied Radiation and Isotopes

Volumn 65, Issue 3, 2007, Pages 301-308

  Das, Tapas ^a   Chakraborty, Sudipta ^a   Banerjee, Sharmila ^a   Venkatesh, Meera ^a  

^a BHABHA ATOMIC RESEARCH CENTRE   (India)

Author keywords

177Lu; DOTA TATE; PRRT; Somatostatin receptors

Indexed keywords

DRUG PRODUCTS; HORMONES; IMPURITIES; LUTETIUM; NEUTRON ACTIVATION ANALYSIS; NEUTRON IRRADIATION APPARATUS; OPTIMIZATION; PROTEINS; RADIOISOTOPES;

RADIOCHEMICAL YIELD; SOMATOSTATIN RECEPTORS; THERAPEUTIC DOSE; THERMAL NEUTRON FLUX;

NUCLEAR REACTORS;

LUTETIUM 177; OCTREOTATE[1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID 3 TYROSINE LU 177]; RADIOPHARMACEUTICAL AGENT;

ARTICLE; BIOREACTOR; COMPLEX FORMATION; CONJUGATE; DRUG SYNTHESIS; HUMAN; IRRADIATION; ISOTOPE LABELING; NEUTRON ACTIVATION ANALYSIS; PEPTIDE RECEPTOR RADIONUCLIDE THERAPY; PRIORITY JOURNAL; QUANTUM YIELD; RADIOACTIVITY; RADIOCHEMISTRY; RADIOISOTOPE THERAPY; SINGLE DRUG DOSE;

DRUG STABILITY; HETEROCYCLIC COMPOUNDS, 1-RING; ISOTOPE LABELING; LUTETIUM; OCTREOTIDE; ORGANOMETALLIC COMPOUNDS; RADIOISOTOPES; RADIOPHARMACEUTICALS;

EID: 33845629888     PISSN: 09698043     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.apradiso.2006.09.011     Document Type: Article

References (28)

1. 177Lu-DOTA-lanreotide: a novel tracer as a targeted agent for tumor therapy. Nucl. Med. Biol. 31 (2004) 753-759
2. Boerman O.C., Oyer W.J.G., and Corstens F.H.M. Radio-labeled receptor-binding peptides: a new class of radiopharmaceuticals. Semin. Nucl. Med. 30 (2000) 195-208
3. Breeman W.A.P., de Jong M., Kwekkeboom D.J., Valkema R., Kooij P.P., Visser T.J., and Krenning E.P. Somatostatin receptor-mediated imaging and therapy: basic science, current knowledge, limitations and future perspectives. Eur. J. Nucl. Med. 28 (2001) 1421-1429
4. 177Lu at high specific activities. Eur. J. Nucl. Med. Mol. Imag. 30 (2003) 917-920
5. Britton K.E. Towards the goal of cancer specific imaging and therapy. Nucl. Med. Commun. 18 (1997) 992-1005
6. 177Lu labeled cyclic polyaminophosphonates as potential agents for bone pain palliation. Appl. Radiat. Isot. 57 (2002) 177-184
7. 177Lu labeled sanazole derivative for possible use in targeting tumor hypoxia. Bioorg. Med. Chem. 12 (2004) 6077-6084
8. 90Y-labeled somatostatin analogues. J. Nucl. Med. 46 (2005) 13S-17S
9. Eckelman W.C., and Gibson R.E. The design of site-directed radiopharmaceuticals for use in drug discovery. In: Burns H.D., Gibson R.E., Dannals R., and Siegl P. (Eds). Nuclear Imaging in Drug Discovery, Development, and Approval (1993), Birkhauser, Boston
10. Firestone R. In: Shirley V.S. (Ed). Table of Isotopes. eighth ed. (1996), Wiley, New York
11. 90Y-DOTATOC. J. Nucl. Med. 46 (2005) 1310-1316
12. Knapp, F.F., Ambrose, K.R., Beets, A.L., Luo, H., McPherson, D.W., Mirzadeh, S., 1995. Nuclear medicine program progress report for quarter ending September 30, 1995. Oak Ridge National Laboratory, pp. 6-16.
13. Krenning E.P., Bakker W.H., Kooij P.P., Breeman W.A., Oei H.Y., de Jong M., Reubi J.C., Visser T.J., Bruns C., and Ikekubo K. Somatostatin receptor scintigraphy with indium-111-DTPA-d-Phe-1-octreotide in man: metabolism, dosimetry and comparison with iodine-123-Tyr-3-octreotide. J. Nucl. Med. 33 (1992) 652-658
14. 3)-octreotide: the Rotterdam experience with more than 1000 patients. Eur. J. Nucl. Med. 20 (1993) 716-731
15. Kwekkeboom D.J., Krenning E.P., and de Jong M. Peptide receptor imaging and therapy. J. Nucl. Med. 41 (2000) 1704-1713
16. 0)octreotide in patients. Eur. J. Nucl. Med. 28 (2001) 1319-1325
17. 3)octreotate. Eur. J. Nucl. Med. Mol. Imag. 30 (2003) 417-422
18. Kwekkeboom D.J., Bakker W.H., Teunissen J.J.M., Kooij P.P.M., and Krenning E.P. Treatment with Lu-177-DOTATyr3-Octerotate in patients with neuroendocrine tumors: interim results. Eur. J. Nucl. Med. Mol. Imag. 30 (2003) S231 [abstract]
19. Kwekkeboom D.J., Muller-Brand J., Paganelli G., Anthony L.B., Pauwels S., Kvols L.K., O'Dorisio T.M., Valkema R., Bodei L., Chinol M., Maecke H.R., and Krenning E.P. Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs. J. Nucl. Med. 46 (2005) 62S-66S
20. Mausner L.F., and Srivastava S.C. Selection of radionuclides for radioimmunotherapy. Med. Phys. 20 (1993) 503-509
21. 177Lu for radioimmunotherapeutic applications. Nucl. Med. Biol. 29 (2002) 431-442
22. Neves M., Kling A., and Lambrecht R.M. Radionuclide production for therapeutic radiopharmaceuticals. Appl. Radiat. Isot. 57 (2002) 657-664
23. 176Lu. J. Radioanal. Nucl. Chem. 262 (2004) 563-567
24. Pauwels E.K.J., McCready V.R., Stoot J.H.M.B., and van Deurzen D.F.P. Mechanism of accumulation of tumour-localising radiopharmaceuticals. Eur. J. Nucl. Med. 25 (1998) 277-305
25. 177Lu for radionuclide therapy. Appl. Radiat. Isot. 59 (2003) 109-117
26. Reubi J.C., Schar J.C., Waser B., Wenger S., Heppeler A., Schmitt J.S., and Macke H.R. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur. J. Nucl. Med. 27 (2000) 273-282
27. Stimmel J.B., and Kull Jr. F.C. Samarium-153 and Lutetium-177 chelation properties of selected macrocyclic and acyclic ligands. Nucl. Med. Biol. 25 (1998) 117-125
28. Volkert W.A., and Hoffman T.J. Therapeutic radiophamaceuticals. Chem. Rev. 99 (1999) 2269-2292